June 14, 2024

The CHU de Québec-Université Laval and Quantino are partnering for the creation of cutting-edge health technologies

Quantino, the high-tech business incubator powered by INO, and the CHU de Québec-Université Laval (CHU) are teaming up to expand the regional offering in incubating companies developing technologies to prevent, diagnose, and treat various diseases – notably cancer and immune diseases – as well as to promote regenerative medicine and women’s health.

image alt


Close CHU and INO

This sharing of expertise in research and development, entrepreneurial services, laboratories, and infrastructure will contribute to the growth and attraction of young companies in the region that are working on the development and marketing of life science technology products. This will result in improved patient care, as the technological and medical innovations from these companies will provide access to more effective treatments, more precise diagnostics, and more advanced health solutions. By fostering a dynamic and collaborative ecosystem, it will be possible to contribute to a better future for the health of the population.

Concretely, this new partnership will result in the provision of real-world care testing for innovative companies supported by Quantino, sharing of research and development infrastructure, and the desire to explore other opportunities.

The Québec region, a 360° service hub for the development of medical technologies

Across Québec, the medical technology industry comprises 397 companies and generates about 15,650 direct jobs. It is a sector that fulfills a very important social mission, especially in the context of an increasing and aging population. Thus, Quantino has already welcomed 8 medical companies, and the collaboration with the CHU will allow the incubator to increase its support capacity and the diversity of the startups that will enter.

“This collaboration between Quantino and the CHU de Québec-Université Laval is a fine example of the capacity to innovate in order to find even more effective remedies and offer innovative treatments to patients. Innovation leads to incredible advances that are directly linked to current and future health priorities and challenges. We can be proud of the determination and creativity of the local teams, who unite their efforts to offer care that is always better adapted to the needs of people,” highlighted the MP for Vanier-Les Rivières, Mario Asselin.

“The collaboration between different organizations as we see today between INO and the CHU is essential to foster the emergence and development of companies. The presence of half a dozen incubators-accelerators in the life sciences field, including Quantino, is also an undeniable asset,” declared the city councilor and member of the executive committee at the City of Québec, Mr. David Weiser. For its part, the City plays a facilitating role by supporting not only the companies in their development but also by ensuring to offer an exceptional quality of life to be attractive to employers."

“For the CHU de Québec-Université Laval, this partnership with Quantino represents an exceptional opportunity to support the development of cutting-edge technologies that will inspire change in health and transform healthcare while improving the quality of life of our patients. This partnership allows us to put our expertise and resources at the service of the advancement of medical science while promoting the emergence of innovative companies with high added value for the community,” said Mr. Martin Beaumont, CEO of the CHU de Québec-Université Laval.

For his part, Mr. Alain Chandonnet, CEO of INO, added that “the contribution of the CHU de Québec for the selection, mentoring of the incubated companies, and the sharing of R&D infrastructure, combined with Quantino’s partnerships with the Institut universitaire de cardiologie et de pneumologie de Québec and the CERVO Research Center, now means that Quantino can welcome emerging technology companies from almost all spheres of the medical world within its walls.”